missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ Human I-TAC (CXCL11) Recombinant Protein, PeproTech®
Click to view available options
Cantidad:
1 mg
100 μg
20 μg
250 μg
50 μg
500 μg
5 μg
Tamaño de la unidad:
1 miligramo
100 microgramos
20 microgramos
250 microgramos
5 microgramos
50 microgramos
500 microgramos
Descripción
Recombinant Human I-TAC is an 8.3 kDa protein containing 73 amino acid residues, including the four highly conserved cysteine residues present in CXC chemokines. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Interferon-inducible T-cell alpha chemoattractant ( I-TAC), belonging to the CXC chemokine family, is expressed in peripheral blood leukocytes, pancreas and liver, thymus, spleen, lung, small intestine, placenta and prostate. Its molecular weight is 8-11 kD. I-TAC is also known as CXCL-11 and IP-9. The cytokine is involved in regulating calcium release and inducing a chemotactic response in activated T-cells and is the dominant ligand for CXC receptor-3. The gene encoding this protein contains 4 exons and at least three polyadenylation signals which might reflect cell-specific regulation of expression. IFN-gamma is a potent inducer of transcription of this gene. It is upregulated in patients with AIDS, dementia and in patients with multiple sclerosis.

Especificaciones
Especificaciones
Número de acceso | O14625 |
Para utilizar con (aplicación) | ELISA, Functional Assay, Western Blot |
Formulación | protein with no preservative |
ID de gen (Entrez) | 6373 |
Peso molecular | 8.3 kDa |
Nombre | Human I-TAC (CXCL11) |
Cantidad | 100 μg |
Fuente | E. coli |
Estado normativo | RUO |
Concentración de endotoxinas | <1 EU/ μg |
Mostrar más |
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto
Gibco™ Human I-TAC (CXCL11) Recombinant Protein, PeproTech® >
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido